Latest

``` Microsoft is developing a more powerful form of artificial intelligence, called "superintelligence," with hopes of making advances in areas such as medicine and materials science. On November 6, Mustafa Suleyman, head of Microsoft’s AI division, published a blog post announcing that he will lead the newly established

``` Recently, China CICC Wealth Securities Co., Ltd. (hereinafter referred to as "CICC Wealth") disclosed a senior management appointment announcement. Chen Liang was appointed chairman of CICC Wealth, meaning that the chairman of CICC now serves as chairman of both the parent company and its subsidiary, overseeing the "

``` Recently, two subsidiaries of Sunshine Insurance—Sunshine Life and Sunshine Property & Casualty—disclosed their financial data for the first nine months of this year. The announcement shows: For the first three quarters of 2025, Sunshine Life and Sunshine Property & Casualty saw their net profits increase by 3.4%

``` J.P. Morgan strategists predict that strong capital inflows from retail investors will support U.S. stocks, and this momentum is expected to continue until the end of the year. According to media reports, the J.P. Morgan strategist team led by Nikolaos Panigirtzoglou pointed out in their latest research

``` The U.S. Supreme Court's ruling on presidential tariff powers may become a major variable in the markets by the end of the year. According to media reports, on Wednesday local time, Supreme Court justices expressed skepticism in oral arguments about Trump's authority to impose tariffs

``` After an astonishing 36% surge since hitting its April low, the U.S. stock market is now facing a valuation warning, according to the indicator favored by investment legend Warren Buffett. Latest data shows that the "Buffett Indicator" has surpassed the historic record set during the pandemic, a

``` Lilly is consolidating its leading position in the weight-loss drug market through both new drug development and policy cooperation. On November 6, Lilly announced that its experimental weight-loss drug eloralintide helped patients lose 20.1% of their weight in a mid-stage trial and will launch late-stage clinical trials next month.